NCT02556892 2019-08-14
A Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Janssen Pharmaceutical K.K.
Phase 1 Completed
Janssen Pharmaceutical K.K.
Pharmacyclics LLC.
Pharmacyclics LLC.